+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cannabis Pharmaceuticals Market - Global Forecast 2026-2032- Product Image
Cannabis Pharmaceuticals Market - Global Forecast 2026-2032- Product Image
Sale

Cannabis Pharmaceuticals Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6010641
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cannabis Pharmaceuticals Market is projected to reach USD 4.70 Billion in 2026. It is expected to continue growing at a CAGR of 21.57%, reaching USD 15.23 Billion by 2032.

Cannabis pharmaceuticals are moving from fragmented wellness narratives into a regulated biopharmaceutical category anchored in cannabinoid science, prescription drug development, and evidence-based patient access. The field is shaped by approved cannabinoid medicines, including FDA-approved cannabidiol oral solution for rare seizure disorders such as Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex, as well as synthetic THC products used for chemotherapy-induced nausea and appetite stimulation.

Growth in cannabis-based pharmaceuticals is being driven by unmet needs in neurology, oncology supportive care, pain management research, spasticity, and palliative care. At the same time, strict controlled-substance scheduling, inconsistent national frameworks, product-quality requirements, and the need for randomized clinical evidence continue to define commercialization timelines, reimbursement pathways, physician adoption, and patient access.

Transformative Shifts in the Cannabis Pharmaceutical Landscape

The cannabis pharmaceuticals landscape is shifting from plant-access programs toward standardized, clinically validated cannabinoid formulations. Regulators and payers increasingly require consistent active pharmaceutical ingredient profiles, pharmacokinetic data, safety monitoring, adverse-event reporting, and randomized clinical trial evidence rather than broad claims based on cannabis use.

A second major shift is the separation of pharmaceutical cannabinoids from consumer cannabis. Organizations with GMP manufacturing, validated extraction or synthesis methods, intellectual property protection, stability data, and pharmacovigilance capabilities are better positioned as hospitals, insurers, and physicians prioritize dose precision, drug-drug interaction evidence, route-of-administration control, and predictable therapeutic outcomes.

Cumulative Impact of Artificial Intelligence on Cannabis Pharmaceuticals

Artificial intelligence is compounding the pace of cannabinoid drug discovery by supporting target identification, molecule screening, formulation optimization, and clinical trial design. AI-enabled literature mining and multi-omics analysis can help identify receptor pathways beyond CB1 and CB2, including inflammatory, neuronal, immune, and pain-related mechanisms relevant to cannabinoid-based therapies.

The cumulative impact is strongest when AI is paired with validated datasets, regulatory-grade evidence, and human clinical oversight. Practical applications include patient stratification, adverse event signal detection, drug interaction monitoring, synthetic cannabinoid design support, real-world evidence analysis, and trial recruitment optimization, all of which can reduce development uncertainty without replacing controlled clinical trials.

Key Regional Insights Across Global Cannabis Pharmaceutical Markets

North America remains the most advanced region for cannabis pharmaceuticals because the United States has a defined FDA pathway for approved cannabinoid medicines while Canada operates a federally regulated medical cannabis system with established licensing, quality, and patient-access mechanisms. Europe is shaped by country-level reimbursement and prescribing rules under broader pharmaceutical quality expectations, with Germany, the United Kingdom, Italy, France, and Spain serving as important clinical, regulatory, and access markets for cannabinoid-based medicines.

Asia-Pacific presents long-term potential through Australia’s regulated medicinal cannabis access, Japan’s cautious pharmaceutical orientation following reforms that support approved cannabis-derived medicines while maintaining strict controls on non-medical use, and emerging reforms in selected markets. Latin America is led by Brazil and Mexico’s evolving medical access frameworks, with Brazil maintaining regulated pathways for cannabis-based products under health authority oversight. The Middle East and Africa remain highly selective, with access concentrated in tightly controlled medical, research, or import-based channels, while strict narcotics-control regimes continue to shape adoption across many countries.

Key Group Insights for Cannabis Pharmaceutical Strategy

The European Union is central to regulatory harmonization, clinical evidence standards, pharmacovigilance expectations, and cross-border pharmaceutical quality requirements, although cannabis prescribing still varies by member state. G7 countries influence global norms through strong drug regulators, clinical research infrastructure, research funding, intellectual property systems, controlled-substance oversight, and payer scrutiny.

BRICS markets offer scale and scientific capacity but require country-specific navigation across China, India, Brazil, Russia, and South Africa, where cannabis policy ranges from strict prohibition to controlled medical access. ASEAN remains cautious and heterogeneous despite Thailand’s policy changes and ongoing regulatory recalibration, while GCC markets emphasize strict narcotics control and limited medical authorization. NATO alignment is indirect but relevant through member-state medical procurement, security rules, controlled-substance compliance, and harmonized expectations for pharmaceutical supply-chain integrity.

Key Country Insights for Cannabis Pharmaceutical Expansion

The United States is defined by FDA-approved cannabinoid drugs, federal-state cannabis divergence, Schedule I constraints for botanical cannabis, and strong clinical trial infrastructure. Canada offers federal medical access and manufacturing experience, while Mexico and Brazil are developing regulated access with significant patient need and evolving health authority oversight. The United Kingdom, Germany, France, Italy, and Spain represent Europe’s core commercial and clinical opportunities, though reimbursement, prescribing eligibility, compassionate-use rules, and pharmacy distribution requirements differ materially by country.

China and India provide pharmaceutical manufacturing scale, scientific capacity, and traditional medicine complexity, although strict narcotics laws limit broad cannabis pharmaceutical openness. Japan and South Korea maintain conservative but research-relevant environments, with Japan moving toward acceptance of approved cannabis-derived medicines under tightly controlled conditions. Australia is a leading Asia-Pacific access market supported by medicinal cannabis prescribing pathways and regulatory oversight, while Russia remains constrained by strict controlled-substance policy and limited openness to cannabis pharmaceuticals.

Actionable Recommendations for Cannabis Pharmaceutical Leaders

Industry leaders should prioritize prescription-grade evidence, not category hype. The most defensible strategies include GMP-certified manufacturing, validated cannabinoid characterization, impurity control, stability testing, clinical endpoints acceptable to regulators, and pharmacovigilance systems that can withstand scrutiny from agencies, payers, ethics committees, and hospital formularies.

Organizations should also build regional market-entry playbooks that address scheduling, import permits, clinical trial authorization, physician education, reimbursement evidence, product serialization, and patient registry requirements. Partnerships with academic medical centers, contract research organizations, analytical laboratories, and AI-enabled analytics specialists can accelerate development while maintaining the scientific rigor required for durable market access.

Research Methodology for Evidence-Based Market Assessment

This executive summary is based on a structured secondary-research approach using publicly available information from recognized regulators, health agencies, clinical trial registries, peer-reviewed literature, pharmacopeial and GMP guidance, controlled-substance policy sources, and official medical cannabis access frameworks. Priority was given to verifiable facts related to drug approvals, medical access systems, clinical development, prescribing controls, and pharmaceutical quality standards.

The analysis applies regional, group, and country segmentation to assess regulatory maturity, commercial readiness, research capacity, manufacturing capability, reimbursement complexity, and patient access. Insights were synthesized to support strategic planning and executive decision-making without relying on unsupported market claims, market sizing, market share, or forecasting.

Conclusion: Evidence, Access, and Innovation Define the Market

Cannabis pharmaceuticals are entering a more disciplined phase in which clinical evidence, regulatory credibility, controlled-substance compliance, and manufacturing consistency determine long-term value. Approved cannabinoid medicines have validated the pharmaceutical pathway, but broader adoption depends on stronger disease-specific data, clearer reimbursement, responsible prescribing, and reliable quality systems.

The most competitive organizations will combine cannabinoid expertise with drug-development discipline, AI-enabled research capabilities, and region-specific access strategies. As global frameworks evolve, the market will reward stakeholders that can translate cannabis science into safe, standardized, clinically validated, and medically accepted therapies.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Cannabis Pharmaceuticals Market, by Product Type
7.1. Introduction
7.2. Capsule
7.2.1. Hard Shell
7.2.2. Soft Gel
7.3. Oil
7.3.1. Broad Spectrum
7.3.2. Full Spectrum
7.3.3. Isolate
7.4. Patch
7.5. Tincture
7.6. Topical
7.6.1. Cream
7.6.2. Lotion
7.6.3. Salve
8. Cannabis Pharmaceuticals Market, by Compound Type
8.1. Introduction
8.2. CBD
8.3. THC
9. Cannabis Pharmaceuticals Market, by Route Of Administration
9.1. Introduction
9.2. Inhalation
9.3. Oral
9.4. Sublingual
9.5. Topical
10. Cannabis Pharmaceuticals Market, by Application
10.1. Introduction
10.2. Dermatology
10.3. Neurological Disorders
10.4. Oncology Support
10.5. Pain Management
11. Cannabis Pharmaceuticals Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Homecare
11.4. Hospitals
11.5. Specialized Centers
12. Cannabis Pharmaceuticals Market, by Distribution Channel
12.1. Introduction
12.2. Direct To Patient Sales
12.3. Hospital Pharmacies
12.4. Online Pharmacies
12.5. Retail Pharmacies
13. Cannabis Pharmaceuticals Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Cannabis Pharmaceuticals Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. Cannabis Pharmaceuticals Market, by Country
15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. Aphria, Inc.
17.3. Aurora Cannabis, Inc.
17.4. Bausch Health Companies, Inc.
17.5. Botanix Pharmaceuticals
17.6. Breath of Life Pharma, Ltd.
17.7. Cannabis Science, Inc.
17.8. Cannamedical Pharma GmbH
17.9. Canopy Growth Corporation
17.10. Cara Therapeutics Inc.
17.11. CB Therapeutics Inc.
17.12. Celadon Pharmaceuticals PLC
17.13. Corbus Pharmaceuticals Holdings, Inc.
17.14. Cronos Group Inc. By Altria Group
17.15. Green Thumb Industries
17.16. Jazz Pharmaceuticals PLC
17.17. Medical Marijuana Inc.
17.18. MGC Pharmaceuticals Limited
17.19. Panaxia Pharmaceutical Industries
17.20. Pascal Biosciences Inc.
17.21. PharmaCyte Biotech, Inc.
17.22. Renew Biopharma, Inc.
17.23. Teva Pharmaceutical Industries Ltd.
17.24. Tilray Brands, Inc.
17.25. Zynerba Pharmaceuticals, Inc. by Harmony Biosciences
List of Figures
FIGURE 1. GLOBAL CANNABIS PHARMACEUTICALS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CANNABIS PHARMACEUTICALS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CANNABIS PHARMACEUTICALS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CANNABIS PHARMACEUTICALS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL CANNABIS PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL CANNABIS PHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL CANNABIS PHARMACEUTICALS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL HARD SHELL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL HARD SHELL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL HARD SHELL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL SOFT GEL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL SOFT GEL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL SOFT GEL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL OIL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL OIL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL OIL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL BROAD SPECTRUM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL BROAD SPECTRUM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL BROAD SPECTRUM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL FULL SPECTRUM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL FULL SPECTRUM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL FULL SPECTRUM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL ISOLATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ISOLATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ISOLATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL PATCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL PATCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PATCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL TINCTURE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL TINCTURE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL TINCTURE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CREAM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL CREAM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL CREAM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL LOTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL LOTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL LOTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL SALVE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL SALVE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SALVE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL CBD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL CBD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL CBD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL THC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL THC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL THC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL INHALATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL SUBLINGUAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL SUBLINGUAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL SUBLINGUAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL DERMATOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL DERMATOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL DERMATOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ONCOLOGY SUPPORT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ONCOLOGY SUPPORT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ONCOLOGY SUPPORT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL HOMECARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL HOMECARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HOMECARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL SPECIALIZED CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL SPECIALIZED CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL SPECIALIZED CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL DIRECT TO PATIENT SALES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL DIRECT TO PATIENT SALES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL DIRECT TO PATIENT SALES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC CANNABIS PHARMACEUTICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 113. EUROPE CANNABIS PHARMACEUTICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. EUROPE CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 115. EUROPE CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 116. EUROPE CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 117. EUROPE CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 118. EUROPE CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 119. EUROPE CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 120. EUROPE CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 121. EUROPE CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 122. EUROPE CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. NORTH AMERICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 125. NORTH AMERICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 126. NORTH AMERICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 127. NORTH AMERICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 128. NORTH AMERICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 129. NORTH AMERICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 130. NORTH AMERICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 131. NORTH AMERICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 132. NORTH AMERICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 133. LATIN AMERICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. LATIN AMERICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 135. LATIN AMERICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 136. LATIN AMERICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 137. LATIN AMERICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 138. LATIN AMERICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 139. LATIN AMERICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 140. LATIN AMERICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 141. LATIN AMERICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 142. LATIN AMERICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 143. AFRICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 144. AFRICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 145. AFRICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 146. AFRICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 147. AFRICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 148. AFRICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 149. AFRICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 150. AFRICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 151. AFRICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 152. AFRICA CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 153. MIDDLE EAST CANNABIS PHARMACEUTICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 154. MIDDLE EAST CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 155. MIDDLE EAST CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 156. MIDDLE EAST CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 157. MIDDLE EAST CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 158. MIDDLE EAST CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 159. MIDDLE EAST CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 160. MIDDLE EAST CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 161. MIDDLE EAST CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 162. MIDDLE EAST CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 164. NATO CANNABIS PHARMACEUTICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 165. NATO CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 166. NATO CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 167. NATO CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 168. NATO CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 169. NATO CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 170. NATO CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 171. NATO CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 172. NATO CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 173. NATO CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 174. G7 CANNABIS PHARMACEUTICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 175. G7 CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 176. G7 CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 177. G7 CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 178. G7 CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 179. G7 CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 180. G7 CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 181. G7 CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 182. G7 CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 183. G7 CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 184. BRICS CANNABIS PHARMACEUTICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 185. BRICS CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 186. BRICS CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 187. BRICS CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 188. BRICS CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 189. BRICS CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 190. BRICS CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 191. BRICS CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 192. BRICS CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 193. BRICS CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION CANNABIS PHARMACEUTICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 202. EUROPEAN UNION CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 204. ASEAN CANNABIS PHARMACEUTICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 205. ASEAN CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 206. ASEAN CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 207. ASEAN CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 208. ASEAN CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 209. ASEAN CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 210. ASEAN CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 211. ASEAN CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 212. ASEAN CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 213. ASEAN CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 214. GCC CANNABIS PHARMACEUTICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 215. GCC CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 216. GCC CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 217. GCC CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 218. GCC CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 219. GCC CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 220. GCC CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 221. GCC CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 222. GCC CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 223. GCC CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 224. GLOBAL CANNABIS PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 225. CHINA CANNABIS PHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 226. CHINA CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 227. CHINA CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 228. CHINA CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 229. CHINA CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 230. CHINA CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 231. CHINA CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 232. CHINA CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 233. CHINA CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 234. CHINA CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 235. UNITED STATES CANNABIS PHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 237. UNITED STATES CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 241. UNITED STATES CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 242. UNITED STATES CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 243. UNITED STATES CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 244. UNITED STATES CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 245. JAPAN CANNABIS PHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 246. JAPAN CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 247. JAPAN CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 248. JAPAN CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 249. JAPAN CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 250. JAPAN CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 251. JAPAN CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 252. JAPAN CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 253. JAPAN CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 254. JAPAN CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 255. INDIA CANNABIS PHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 256. INDIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 257. INDIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 258. INDIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 259. INDIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 260. INDIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 261. INDIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 262. INDIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 263. INDIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 264. INDIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 265. GERMANY CANNABIS PHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 266. GERMANY CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 267. GERMANY CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 268. GERMANY CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 269. GERMANY CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 270. GERMANY CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 271. GERMANY CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 272. GERMANY CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 273. GERMANY CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 274. GERMANY CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 275. UNITED KINGDOM CANNABIS PHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 276. UNITED KINGDOM CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 277. UNITED KINGDOM CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 278. UNITED KINGDOM CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 279. UNITED KINGDOM CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 280. UNITED KINGDOM CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 281. UNITED KINGDOM CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 282. UNITED KINGDOM CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 283. UNITED KINGDOM CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 284. UNITED KINGDOM CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 285. AUSTRALIA CANNABIS PHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 286. AUSTRALIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 287. AUSTRALIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 288. AUSTRALIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 289. AUSTRALIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 290. AUSTRALIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 291. AUSTRALIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 292. AUSTRALIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 293. AUSTRALIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 294. AUSTRALIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 295. FRANCE CANNABIS PHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 296. FRANCE CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 297. FRANCE CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 298. FRANCE CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 299. FRANCE CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 300. FRANCE CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 301. FRANCE CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 302. FRANCE CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 303. FRANCE CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 304. FRANCE CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 305. SOUTH KOREA CANNABIS PHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 306. SOUTH KOREA CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 307. SOUTH KOREA CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 308. SOUTH KOREA CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 309. SOUTH KOREA CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 310. SOUTH KOREA CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 311. SOUTH KOREA CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 312. SOUTH KOREA CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 313. SOUTH KOREA CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 314. SOUTH KOREA CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 315. ITALY CANNABIS PHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 316. ITALY CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 317. ITALY CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 318. ITALY CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 319. ITALY CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 320. ITALY CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 321. ITALY CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 322. ITALY CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 323. ITALY CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 324. ITALY CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 325. CANADA CANNABIS PHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 326. CANADA CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 327. CANADA CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 328. CANADA CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 329. CANADA CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 330. CANADA CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 331. CANADA CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 332. CANADA CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 333. CANADA CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 334. CANADA CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 335. RUSSIA CANNABIS PHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 336. RUSSIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 337. RUSSIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 338. RUSSIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 339. RUSSIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 340. RUSSIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 341. RUSSIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 342. RUSSIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 343. RUSSIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 344. RUSSIA CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 345. BRAZIL CANNABIS PHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 346. BRAZIL CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 347. BRAZIL CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 348. BRAZIL CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 349. BRAZIL CANNABIS PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 350. BRAZIL CANNABIS PHARMACEUTICALS MARKET SIZE, BY COMPOUND TYPE, 2017-2032 (USD MILLION)
TABLE 351. BRAZIL CANNABIS PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 352. BRAZIL CANNABIS PHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 353. BRAZIL CANNABIS PHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 354. BRAZIL CANNABIS PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 355. MEXICO CANNABIS PHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 356. MEXICO CANNABIS PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 357. MEXICO CANNABIS PHARMACEUTICALS MARKET SIZE, BY CAPSULE, 2017-2032 (USD MILLION)
TABLE 358. MEXICO CANNABIS PHARMACEUTICALS MARKET SIZE, BY OIL, 2017-2032 (USD MILLION)
TABLE 359. MEXICO CANNABIS PHARMACEU

Companies Mentioned

  • AbbVie Inc.
  • Aphria, Inc.
  • Aurora Cannabis, Inc.
  • Bausch Health Companies, Inc.
  • Botanix Pharmaceuticals
  • Breath of Life Pharma, Ltd.
  • Cannabis Science, Inc.
  • Cannamedical Pharma GmbH
  • Canopy Growth Corporation
  • Cara Therapeutics Inc.
  • CB Therapeutics Inc.
  • Celadon Pharmaceuticals PLC
  • Corbus Pharmaceuticals Holdings, Inc.
  • Cronos Group Inc. By Altria Group
  • Green Thumb Industries
  • Jazz Pharmaceuticals PLC
  • Medical Marijuana Inc.
  • MGC Pharmaceuticals Limited
  • Panaxia Pharmaceutical Industries
  • Pascal Biosciences Inc.
  • PharmaCyte Biotech, Inc.
  • Renew Biopharma, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Tilray Brands, Inc.
  • Zynerba Pharmaceuticals, Inc. by Harmony Biosciences

Table Information

Report AttributeDetails
No. of Pages185
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 4.7 Billion
Forecasted Market Value ( USD ) by 2032 $ 15.23 Billion
Compound Annual Growth Rate21.5%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Cannabis Extraction Market - Global Forecast 2026-2032 - Product Image

Cannabis Extraction Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Cannabis Market - Global Forecast 2026-2032 - Product Image

Cannabis Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Cannabis Extract - Global Strategic Business Report - Product Image

Cannabis Extract - Global Strategic Business Report

  • Report
  • 278 Pages
  • Global
From
Cannabis Pharmaceuticals - Global Strategic Business Report - Product Image

Cannabis Pharmaceuticals - Global Strategic Business Report

  • Report
  • 116 Pages
  • Global
From
Medical Cannabis Market Report by Species, Derivatives, Application, End-Use, Route of Administration, and Region 2026-2034 - Product Image

Medical Cannabis Market Report by Species, Derivatives, Application, End-Use, Route of Administration, and Region 2026-2034

  • Report
  • 150 Pages
  • Global
From

About the Cannabis Pharmaceuticals Market

The Cannabis Pharmaceuticals market within the context of Analgesics is a rapidly growing sector of the pharmaceutical industry. Cannabis-based pharmaceuticals are used to treat a variety of conditions, including chronic pain, inflammation, and neurological disorders. These drugs are often used in combination with traditional analgesics to provide a more comprehensive approach to pain management. Cannabis-based pharmaceuticals are also being studied for their potential to reduce opioid dependence and addiction. Cannabis-based pharmaceuticals are available in a variety of forms, including oral capsules, topical creams, and sublingual sprays. These products are often formulated with other active ingredients, such as cannabinoids, terpenes, and flavonoids, to provide additional therapeutic benefits. Several companies are currently operating in the Cannabis Pharmaceuticals market, including GW Pharmaceuticals, Tilray, and Zynerba Pharmaceuticals. These companies are focused on developing and commercializing cannabis-based pharmaceuticals for the treatment of various conditions. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.